| AMERISOURCEBERGEN |
AMERISOURCEBERGEN |
92%
|
We engage Integrated Commercialization Solutions, a division of AmerisourceBergen Specialty Group, a subsidiary of AmerisourceBergen, to act as our exclusive distributor for commercial shipment and d… |
| CARDINAL-HEALTH-105-INC |
CARDINAL-HEALTH-105-INC |
92%
|
We also contract with numerous wholesale distributors, including Cardinal Health 105, Inc., also known as Specialty Pharmaceutical Services ("Cardinal"), McKesson Corporation and Cencora Inc. (former… |
| INTEGRATED-COMMERCIALIZATION-SOLUTIONS |
INTEGRATED-COMMERCIALIZATION-SOLUTIONS |
92%
|
We engage Integrated Commercialization Solutions, a division of AmerisourceBergen Specialty Group, a subsidiary of AmerisourceBergen, to act as our exclusive distributor for commercial shipment and d… |
| HYPERCON-TECHNOLOGY-COLLABORATION-PARTNERS |
HYPERCON-TECHNOLOGY-COLLABORATION-PARTNERS |
90%
|
The collaboration partner is responsible for all development, manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement |
| ORKA |
Oruka Therapeutics, Inc. |
85%
|
les of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration and one commercial product from each of the Takeda, argenx and BMS collaborations.… |
| ORKA |
Oruka Therapeutics, Inc. |
85%
|
Reciprocal relationship from ORKA graph: Reciprocal relationship from HALO graph: Reciprocal relationship from ORKA graph: Reciprocal relationship from HALO graph: Reciprocal relationship from ORKA g… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
85%
|
les of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration and one commercial product from each of the Takeda, argenx and BMS collaborations.… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
85%
|
Reciprocal relationship from VRTX graph: Reciprocal relationship from HALO graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from HALO graph: Reciprocal relationship from VRTX g… |
| AMPH |
Amphastar Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from AMPH graph: Reciprocal relationship from HALO graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from HALO graph: Reciprocal relationship from AMPH g… |
| AMPH |
Amphastar Pharmaceuticals, Inc. |
72%
|
nce Marketplaces, has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including our partners’ products, are covered and re… |
| MCK |
McKesson Corporation |
72%
|
Contents Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surgery center customers with the information needed to obtain formulary approval for,… |
| MCK |
McKesson Corporation |
72%
|
Reciprocal relationship from MCK graph: Reciprocal relationship from HALO graph: Reciprocal relationship from MCK graph: Reciprocal relationship from HALO graph: Reciprocal relationship from MCK grap… |
| ZLAB |
Zai Lab Limited |
72%
|
ds. We target large, attractive markets, where ENHANZE-enabled SC delivery has the potential to deliver competitive differentiation and other important benefits to our partners, such as larger inject… |
| ZLAB |
Zai Lab Limited |
72%
|
Reciprocal relationship from ZLAB graph: Reciprocal relationship from HALO graph: Reciprocal relationship from ZLAB graph: Reciprocal relationship from HALO graph: Reciprocal relationship from ZLAB g… |
| AMERISOURCEBERGEN-CORPORATION |
AMERISOURCEBERGEN-CORPORATION |
62%
|
XYOSTED. Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surgery center customers with the information needed to obtain formulary approval for,… |
| AMERISOURCEBERGEN-SPECIALTY-GROUP |
AMERISOURCEBERGEN-SPECIALTY-GROUP |
62%
|
XYOSTED. Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surgery center customers with the information needed to obtain formulary approval for,… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
$ (13,025) (70) % The decrease in revenues under collaborative agreements was primarily due to the timing of milestones achieved. Revenue from upfront licenses fees, license fees for the election of … |
| CATALENT-INDIANA-LLC |
CATALENT-INDIANA-LLC |
62%
|
d supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada. We are the exclusive supplier of the device, which we developed, for Teva’s generic Epine… |
| COMDEL-INNOVATION-INC |
COMDEL-INNOVATION-INC |
62%
|
-injector product with Teva. • ComDel Innovation, Inc., a domestic provider of integrated solutions for product development, tooling, and manufacturing, produces commercial quantities of components f… |
| HALOZYME-HYPERCON-INC |
HALOZYME-HYPERCON-INC |
62%
|
les of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration and one commercial product from each of the Takeda, argenx and BMS collaborations.… |
| IDORSIA-PHARMACEUTICALS-LTD |
IDORSIA-PHARMACEUTICALS-LTD |
62%
|
cense, development and supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada. We are the exclusive supplier of the device, which we developed, for… |
| KNIPPER-HEALTH-INC |
KNIPPER-HEALTH-INC |
62%
|
XYOSTED. Sales, Marketing and Distribution We have two teams of sales specialists, one that provide hospital and surgery center customers with the information needed to obtain formulary approval for,… |
| LONZA-SALES-AG |
LONZA-SALES-AG |
62%
|
d supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada. We are the exclusive supplier of the device, which we developed, for Teva’s generic Epine… |
| MCDERMOTT-LABORATORIES-LIMITED |
MCDERMOTT-LABORATORIES-LIMITED |
62%
|
cense, development and supply agreement with Teva for an epinephrine auto- injector product to be marketed in the U.S. and Canada. We are the exclusive supplier of the device, which we developed, for… |
| NOLATO-CONTOUR-INC |
NOLATO-CONTOUR-INC |
62%
|
onal contract packaging company, assembles and packages XYOSTED auto-injector products and the OTREXUP auto-injector product for Otter. • Nolato Contour, Inc. produces commercial quantities of compon… |
| PHILLIPS-MEDISIZE-CORPORATION |
PHILLIPS-MEDISIZE-CORPORATION |
62%
|
facturing Services, LLC (“Patheon”) under which Patheon will provide the final fill and finishing steps in the production process of Hylenex recombinant. Devices We also use third parties to manufact… |
| ROCHE-GROUP |
ROCHE-GROUP |
62%
|
nds. We target large, attractive markets, where ENHANZE-enabled SC delivery has the potential to deliver competitive differentiation and other important benefits to our partners, such as larger injec… |
| SURF-BIO-INC |
SURF-BIO-INC |
62%
|
cember 22, 2025, we acquired all outstanding equity interests of Surf Bio, Inc. according to the terms and conditions of the Agreement and Plan of Merger dated as of December 18, 2025 (the “Surf Bio … |
| TEVA |
Teva Pharmaceutical Industries Limited |
62%
|
Reciprocal relationship from TEVA graph: Reciprocal relationship from HALO graph: Reciprocal relationship from TEVA graph: Reciprocal relationship from HALO graph: Reciprocal relationship from TEVA g… |
| TEVA-PHARMACEUTICAL-INDUSTRIES-LTD |
TEVA-PHARMACEUTICAL-INDUSTRIES-LTD |
62%
|
les of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration and one commercial product from each of the Takeda, argenx and BMS collaborations.… |
